|
Market Closed -
Toronto S.E.
01:23:15 10/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.4600 CAD | -1.08% |
|
-3.16% | +1.10% |
| 27/08 | Pharmacorp Rx Inc. Announces Board and Committee Changes, Effective from August 31, 2026 | CI |
| 20/08 | PharmaCorp Rx Swings to Q2 Profit as Revenue Jumps | MT |
Company Valuation: PharmaCorp Rx Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 63.34 | 75.95 | 80.08 | - | - |
| Change | - | 19.91% | 5.43% | - | - |
| Enterprise Value (EV) 1 | 63.34 | 53.55 | 86.68 | 87.53 | 84.45 |
| Change | - | -15.46% | 61.88% | 0.98% | -3.52% |
| P/E | -54x | -45.5x | 46x | 15.3x | - |
| PBR | - | - | - | - | - |
| PEG | - | - | -0x | 0x | - |
| Capitalization / Revenue | - | 3.64x | 1.58x | 0.82x | 0.94x |
| EV / Revenue | - | 2.56x | 1.71x | 0.89x | 0.99x |
| EV / EBITDA | - | 15.2x | 21.3x | 8.24x | 7.51x |
| EV / EBIT | - | - | 50.1x | 13.4x | 22.6x |
| EV / FCF | - | 27.9x | -70.6x | 16.8x | 11.5x |
| FCF Yield | - | 3.58% | -1.42% | 5.97% | 8.68% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.01 | -0.01 | 0.01 | 0.03 | - |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 20.89 | 50.61 | 98.12 | 85.37 |
| EBITDA 1 | - | 3.528 | 4.061 | 10.62 | 11.24 |
| EBIT 1 | - | - | 1.731 | 6.508 | 3.737 |
| Net income 1 | -1.013 | -1.481 | 1.5 | 6.7 | - |
| Net Debt 1 | - | -22.4 | 6.603 | 7.451 | 4.371 |
| Reference price 2 | 0.5400 | 0.4550 | 0.4600 | 0.4600 | 0.4600 |
| Nbr of stocks (in thousands) | 1,17,296 | 1,66,927 | 1,74,082 | - | - |
| Announcement Date | 22/04/25 | 29/04/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 46x | 1.71x | 21.34x | - | 5.8Cr | |
| 16.08x | 0.63x | 9.38x | -.--% | 1.43TCr | |
| 16.37x | 0.73x | 7.65x | 2.27% | 647.93Cr | |
| 20.28x | 0.76x | 12.85x | 1.1% | 628.72Cr | |
| 14.64x | 0.9x | 6.2x | 2.87% | 412.12Cr | |
| 14.45x | 1.24x | 7.59x | 5.57% | 321.62Cr | |
| 14.02x | 0.59x | 4.57x | 5.15% | 310.24Cr | |
| 13.24x | 0.79x | 5.91x | 4.91% | 278.07Cr | |
| 35.35x | - | - | - | 274.84Cr | |
| Average | 21.16x | 0.92x | 9.44x | 3.12% | 479.28Cr | |
| Weighted average by Cap. | 17.41x | 0.75x | 8.58x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCRX Stock
- Valuation PharmaCorp Rx Inc.
Select your edition
All financial news and data tailored to specific country editions
